Acute Myeloid Leukemia Prognostic Panel (Normal Ka

The Acute Myeloid Leukemia Prognostic Panel (Normal Ka test contains 1 test.

Acute Myeloid Leukemia Prognostic Panel (Normal Karyotype)

Clinical Significance

This testing, consisting of FLT3, NPM-1, and CEBPA, is recommended in the NCCN guidelines for determination of AML risk status in patients with cytogenetically normal AML. The presence of CEBPA gene mutations is associated with increased disease-free survival and overall survival. Mutations in NPM1 gene is a predictor of favorable prognosis and good response to induction chemotherapy. The presence of (FLT3) internal tandem duplication is associated with short disease-free survival.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: Acute Myeloid Leukemia Prognostic Panel Normal Karyotype

*Process times are an estimate and are not guaranteed. The lab may need additional time due to weather, holidays, confirmation/repeat testing, or equipment maintenance.

Customer Reviews